Chemomab Therapeutics Ltd expected to post a loss of 8 cents a share - Earnings Preview
03/03/2025 12:02
Chemomab Therapeutics Ltd CMMB.OQ CMMB.O is expected to show no change in quarterly revenue when it reports results on March 5 (estimated) for the period ending December 31 2024 LSEG's mean analyst estimate for Chemomab Therapeutics Ltd is for a loss of 8 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Chemomab Therapeutics Ltd is $9.00, above its last closing price of $1.68. This summary was machine generated March 3 at 12:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update